What You Should Know:
– Glooko, a provider of remote patient monitoring and digital health solutions for diabetes, has acquired Monarch Medical Technologies, the developer of the EndoTool® Glucose Management System. Terms of the acquisition are not being disclosed.
– The strategic acquisition allows Glooko to expand its connected care capabilities into inpatient glycemic management, complementing its existing strength in outpatient diabetes management. The goal is to create a single, integrated solution that will support patients and clinicians across the full continuum of care.
Expanding from Outpatient to Inpatient Care
Glooko’s platform, which is used by millions of patients and more than 8,000 clinics worldwide, aggregates data from over 200 connected devices, including blood glucose meters, insulin pumps, and continuous glucose monitors (CGMs). By adding Monarch Medical’s EndoTool, an FDA-cleared software platform for inpatient insulin dosing, Glooko will now support acute care settings with precision insulin dosing algorithms. This integrated approach is intended to reduce hospital readmissions, enhance continuity of care, and improve overall glycemic control across different settings.
Inpatient glycemic management is a critical factor in patient safety, outcomes, and hospital performance, with 30–40% of hospitalized patients requiring insulin therapy. The EndoTool platform uses a patented, patient-specific algorithm to deliver precise, guideline-aligned insulin dosing in real-time. This helps reduce the risk of hypoglycemia and assists hospitals in meeting CMS quality measures while streamlining clinical workflows.
Building on Strategic Growth and Investor Support
This acquisition follows Glooko’s $100M Series F financing round, which was completed in October 2024. At that time, Glooko announced its intent to accelerate growth through both product innovation and selective acquisitions. The addition of Monarch Medical demonstrates how Glooko is using that capital and investor support to expand its connected care platform and solidify its position as a global leader in digital health for diabetes management. The terms of the acquisition were not disclosed, and for the near term, both companies will continue to operate their products as they do today.
